Product Details

Tanezumab biosimilar is a research-grade humanized monoclonal antibody designed to target nerve growth factor (NGF), a protein involved in pain regulation. NGF plays a significant role in the development and maintenance of neurons, and its levels increase during injury, inflammation, or chronic pain conditions. Tanezumab works by binding to and inhibiting NGF, providing an innovative treatment for pain without the risks typically associated with conventional painkillers like opioids. This biosimilar antibody is produced in mammalian cells and is available in multiple sizes for research purposes, with specifications indicating that it is a human IgG2-kappa isotype. It is formulated in PBS at pH 7.4, and it has an endotoxin level of <1 EU per mg. Researchers use it in a variety of studies, including animal models and flow cytometry assays, to explore NGF neutralization and its potential therapeutic applications